Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Osteoarthritis Cartilage. 2015 Dec 31;24(5):776–785. doi: 10.1016/j.joca.2015.12.011

Figure 5. Cost-effectiveness of Tanezumab: Sensitivity to Cost and Rapid OA Progression.

Figure 5

This figure shows the sensitivity of incremental cost-effectiveness ratios to rapid OA progression for Tanezumab added to the standard of care. The figure shows the impact of drug cost ($200 – $1000 per dose), mode and setting of delivery (SC vs IV, self-administered vs non-hospital vs hospital), and rate of rapid OA progression, indicated as ‘toxicity’ (1%, 3%, 5%, 10%). All other variables in this analysis were set to base case values.